 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||||||||||||||||||||||||||||||||
 |
New Study Reports on Improved Disease Detection with the ThinPrep(R) Imaging System
MARLBOROUGH, Mass., (May 15, 2006) - Cytyc Corporation, a leading women's health company, today announced that a study published in the May-June issue of Acta Cytologica reports that implementation of the ThinPrep(R) Imaging System significantly increased detection of cervical squamous intraepithelial lesions compared to manually screened ThinPrep(R) Pap Tests. Acta Cytologica is the official periodical of the International Academy of Cytology. The study, conducted by Dziura et al., at Mercy Medical Center, Springfield, Massachusetts, compared more than 27,000 manually screened ThinPrep Pap Tests with a similar number of ThinPrep Pap Tests screened utilizing the ThinPrep Imaging System. The authors report a statistically significant increase in the detection of all cytologic categories in the ThinPrep Imaging System group. This includes a 30.7 percent increase in the detection of low grade squamous intraepithelial lesions (LSIL), and a 20.0 percent increase in the detection of high grade squamous intraepithelial lesions (HSIL). The increases were statistically significant. The study also confirmed through biopsy results that increased detection of HSIL in the Imaging System group was true disease rather than false positive cytologic diagnoses. The authors concluded, "In this study, the ThinPrep Imaging System proved superior to manual screening in the detection of cervical SIL." "The results of this study continue to demonstrate the clinical effectiveness of our state-of-the-art technology," said Ellen Sheets, M.D., Cytyc's chief medical officer. "We believe the ThinPrep Imaging System provides laboratories, clinicians, and patients the best technology available for cervical cancer screening." About HologicHologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic’s core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. Cytyc’s products cover a range of cancer and women’s health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of patients with early-stage breast cancer. Forward-Looking Statements Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding key customer relationships, future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and customers as well as reliance on proprietary technology, uncertainty of product development efforts and product acceptance, management of growth and product diversification, entry into new market segments domestically and new markets internationally, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies in the United States and abroad, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in its 2005 Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
|
||||||||||||||||||||||||||||||||||||||||
 |
 |
||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
| Home | Women's Health | R2 CAD | Suros Surgical | Skeletal Health | OEM Solutions | Customer Care Center | |||||||||||||||||||||||||||||||||||||||||
| Learning
Center | News & Events | Investor
Relations | About Hologic More Information | Locate Us | Terms of Use | Privacy Policy Copyright 2007 Hologic, Inc. All Rights Reserved. |
|||||||||||||||||||||||||||||||||||||||||